Novartis
NVS
NVS
1,475 hedge funds and large institutions have $18.4B invested in Novartis in 2025 Q4 according to their latest regulatory filings, with 190 funds opening new positions, 487 increasing their positions, 474 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
3% more repeat investments, than reductions
Existing positions increased: 487 | Existing positions reduced: 474
0.04% less ownership
Funds ownership: 6.34% → 6.3% (-0.04%)
38% less call options, than puts
Call options by funds: $382M | Put options by funds: $620M
Holders
1,475
Holding in Top 10
16
Calls
$382M
Puts
$620M
Top Buyers
| 1 | +$150M | |
| 2 | +$117M | |
| 3 | +$103M | |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$79.8M |
| 5 |
VanEck Associates
New York
|
+$67.6M |
Top Sellers
| 1 | -$231M | |
| 2 | -$206M | |
| 3 | -$182M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$112M |
| 5 |
Renaissance Technologies
New York
|
-$70M |
